Tesaro Announces U.S. Fda Approval Of Zejula™ (Niraparib) Ovarian Cancer
g48831msi014.gif
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Clinical trials results for Niraparib in OC. | Download Scientific Diagram
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial - ScienceDirect
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial - The Lancet Oncology
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆ - ScienceDirect
IJGC on Twitter: "How do you treat plat. sens. recurrent #ovariancancer? Would + ICI. improve the results of previous NOVA trial? Check trial protocol of ANITA by Antonio Gonzalez Martin. ➡️https://t.co/CLO2IIwx3D @IGCSociety @
Tesaro begins phase III trial of niraparib for treatment of ovarian cancer – All About Drugs
PARP inhibition in breast cancer: progress made and future hopes | npj Breast Cancer
PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us? - ppt download
Current Oncology | Free Full-Text | A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
PRIMA Study | ZEJULA (niraparib)
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial - The Lancet Oncology
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial - ScienceDirect
Case Discussion: Second Opinion - ppt download
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Niraparib - Zejula als onderhoudsbehandeling bij gevorderde eierstokkanker geeft een veel langere progressievrije overleving bij zowel patiënten met BRCA-gemuteerde eierstokkanker als bij niet BRCA-gemuteerd
SGO 2023: Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial - The Lancet Oncology
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Current Oncology | Free Full-Text | Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer | Nature Communications
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | SpringerLink
![PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d8a6a7200a9b92c47e5ad3f2c4468f771fe2cb38/3-Figure1-1.png "PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar")